microRNAs Role in Pre-eclampsia Diagnosis

Role of Mesenchymal Stem Cells Exosomes Derived microRNAs; miR-136, miR-494 and miR-495 in Pre-eclampsia Diagnosis and Evaluation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03562715

Enrollment

200

Registered

2018-06-19

Start date

2016-11-28

Completion date

2017-12-25

Last updated

2018-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia

Keywords

microRNAs, exosomes, preeclampsia, mesenchymal stem cells

Brief summary

Pre-eclampsia is one of the most threatening pregnancy complications. So far neither a secure, competent therapy for PE nor effective biomarkers for a premature discovery has been achieved.The aim of our study was to identify miRNAs 136, 494 and 495 genes expression in exosomes of peripheral blood compared to umbilical cord mesenchymal stem cells conditioned media released exososomes in patients with PE, as valuable markers for PE early prediction.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

23 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

To have an uncomplicated pregnancy: 1. gestational age at venipuncture between 20 - 42 weeks 2. no medical, obstetrical, or surgical complications 3. absence of labor at the time of venipuncture 4. delivery of a normal term (≥ 37 weeks) neonate whose birth weight was between the 10th and 90th percentile for gestational age

Exclusion criteria

Patients with chronic hypertension, renal disease, and fetuses affected with congenital anomalies were excluded

Design outcomes

Primary

Measure	Time frame
The expression of miRNAs 136, 494 and 495 in exosomes of peripheral blood and UCMSCs conditioned media	2-3 months

Outcome results